NCT03779035 (AdBTC-1) is a Phase 3 clinical trial of Gemcitabine in Cholangiocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT03779035?

NCT03779035 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT03779035?

Interventions in NCT03779035: Gemcitabine, Capecitabine.

What condition does NCT03779035 study?

NCT03779035 studies Cholangiocarcinoma, Gall Bladder Carcinoma.

Is NCT03779035 still recruiting?

NCT03779035 is currently status unknown. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT03779035: AdBTC-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

Status unknown Phase 3 Last updated 19 December 2018

What this trial tests

Phase 3 trial testing Gemcitabine in Cholangiocarcinoma in 460 participants. Status unknown.

Timeline

15 December 2018

Primary endpoint
31 December 2020

31 December 2023

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	460
Start date	15 December 2018
Primary completion	31 December 2020
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Gemcitabine (gemcitabine) — full drug profile →
Capecitabine (capecitabine) — full drug profile →

Conditions studied

Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Gall Bladder Carcinoma — all drugs for Gall Bladder Carcinoma →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

18 and older, any sex, with Cholangiocarcinoma or Gall Bladder Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, open-Label, comparative, randomized, controlled phase III trial was designed to compare the clinical performance of gemcitabine with capecitabine vs. capecitabine alone for patients with biliary tract cancer (BTC) after curative resection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapy of Primary Liver Cancer.
Feng M, Pan Y, Kong R, Shu S. · · 2020 · cited 71× · PMID 32914142 · DOI 10.1016/j.xinn.2020.100032
Gallbladder cancer: current and future treatment options.
Zhou Y, Yuan K, Yang Y, Ji Z, et al · · 2023 · cited 40× · PMID 37251319 · DOI 10.3389/fphar.2023.1183619
Chemotherapy for Biliary Tract Cancer in 2021.
Sasaki T, Takeda T, Okamoto T, Ozaka M, et al · · 2021 · cited 39× · PMID 34300274 · DOI 10.3390/jcm10143108
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.
Sturm N, Schuhbaur JS, Hüttner F, Perkhofer L, et al · · 2022 · cited 32× · PMID 36428670 · DOI 10.3390/cancers14225580
Current progress in perioperative chemotherapy for biliary tract cancer.
Ioka T, Shindo Y, Ueno M, Nagano H. · · 2023 · cited 21× · PMID 37416744 · DOI 10.1002/ags3.12691
Adjuvant therapy of biliary tract cancers.
Kefas J, Bridgewater J, Vogel A, Stein A, et al · · 2023 · cited 16× · PMID 37007632 · DOI 10.1177/17588359231163785
Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022.
Hu ZI, Lim KH. · · 2022 · cited 13× · PMID 35267556 · DOI 10.3390/cancers14051249
Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review.
Hadfield MJ, DeCarli K, Bash K, Sun G, et al · · 2023 · cited 12× · PMID 38203714 · DOI 10.3390/ijms25010543

Verify or expand the search:

Other trials of Gemcitabine

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting

Other recruiting trials for Cholangiocarcinoma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07291947 — PULSAR Combined With Immunotherapy and Chemotherapy · Phase 1, PHASE2 · recruiting
NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03779035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03779035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing